- Home
- ASRT vs AARD Comparison
ASRT vs AARD Comparison
Compare ASRT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | AARD |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 85.7M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASRT | AARD |
|---|---|---|
| Price | $18.04 | $4.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $18.00 | $15.29 |
| AVG Volume (30 Days) | 216.9K | ★ 239.2K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,713,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $3.35 |
| 52 Week High | $20.45 | $17.94 |
Technical Indicators
Market Signals| Indicator | ASRT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 40.80 |
| Support Level | $0.70 | $3.35 |
| Resistance Level | $20.45 | $6.19 |
| Average True Range (ATR) | 1.01 | 0.29 |
| MACD | -0.23 | 0.32 |
| Stochastic Oscillator | 37.03 | 99.57 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.